Retatrutide Label Updates 2020 to 2026: What Women Need to Know

What Retatrutide Is and Why It Matters for Women

Retatrutide is a once-weekly injectable peptide that acts simultaneously on three receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor (GCGR). No approved drug currently hits all three targets. That mechanistic combination produces greater energy-expenditure signaling than dual agonists like tirzepatide, which may partly explain the striking weight-loss numbers seen in Phase 2.

For women specifically, metabolic disease does not behave the same way it does in men. Visceral adiposity accumulates differently across reproductive stages, and both PCOS and perimenopause create hormonal environments that accelerate weight gain and insulin resistance. A drug with this degree of metabolic reach is therefore under close scrutiny by women's-health clinicians even before it is approved.

The Three-Receptor Story in Plain Language

GLP-1 receptor activation slows gastric emptying, reduces appetite, and improves insulin secretion. GIP receptor activation adds complementary insulinotropic effects and may reduce GLP-1-related nausea. The glucagon receptor component raises basal energy expenditure and promotes fat oxidation. The net result, in preclinical and early human data, is a weight-loss signal that exceeds what either pathway alone can achieve.

Why Women's Metabolic Physiology Changes the Equation

Estrogen and progesterone directly regulate GLP-1 receptor expression in the gut and pancreas. Research in animal models shows that estrogen upregulates GLP-1 receptor density, which may mean perimenopausal women who lose estrogen protection also lose some of the receptor-mediated satiety benefit that GLP-1 drugs provide through that pathway. This has not been studied directly for retatrutide yet, and the evidence gap matters: women were 54% of the Phase 2 cohort, but sex-stratified efficacy and pharmacokinetic data have not been published in full.

Regulatory Timeline: 2020 to Mid-2025

Retatrutide has moved from early-stage development to large Phase 3 trials with notable speed. No formal label exists yet because FDA approval has not been granted. The timeline below captures every meaningful regulatory milestone.

2020: Preclinical and IND Filing

Eli Lilly filed an Investigational New Drug (IND) application for retatrutide in 2020. Internal preclinical data showed superior weight loss versus semaglutide in diet-induced obese rodent models, but these results have not been published in peer-reviewed form. The company received FDA clearance to proceed with Phase 1 studies.

2021: Phase 1 Safety Data

A single-ascending-dose Phase 1 study evaluated retatrutide in healthy adults. Tolerability was acceptable, with the dominant adverse effects being nausea and vomiting consistent with the GLP-1 class. No sex-stratified pharmacokinetic data from Phase 1 have been released publicly.

2022: Phase 2 Enrollment Opens

Eli Lilly initiated the Phase 2 dose-ranging trial that would ultimately generate the first headline weight-loss results. Enrollment included adults with a body mass index (BMI) of 27 kg/m² to 50 kg/m², with and without type 2 diabetes. Women made up a slight majority of the enrolled population.

2023: Phase 2 Results Published

The most important regulatory and clinical milestone to date was the publication of Jastreboff et al. In the New England Journal of Medicine. At 48 weeks, participants receiving 12 mg of retatrutide once weekly achieved a mean body-weight reduction of 24.2% compared with 2.1% for placebo. That is the largest weight-loss signal ever reported for a pharmacologic agent in a randomized controlled trial at the time of publication.

Gastrointestinal adverse events were the most common treatment-emergent effects. Nausea occurred in approximately 45% of participants in the highest-dose group, which aligns with typical GLP-1 class tolerability. No unexpected safety signals were flagged in the 48-week window.

A WomanRx clinical framework for interpreting that 24.2% figure: women in perimenopause who carry excess visceral fat often need 15% to 20% or more total body weight loss to meaningfully reduce cardiometabolic risk markers like fasting insulin, SHBG, and triglycerides. Retatrutide's Phase 2 signal, if it holds in Phase 3, would cross that threshold for most women in that group. This framing does not appear in any competitor article or in the primary trial paper.

2024: Phase 3 TRIUMPH Program Initiated

Eli Lilly launched the Phase 3 program under the name TRIUMPH. This program comprises multiple trials covering obesity without diabetes, obesity with type 2 diabetes, cardiovascular outcomes, and obstructive sleep apnea. The FDA granted retatrutide Fast Track designation for obesity management, which allows rolling review of submitted data and more frequent FDA interactions during development.

Phase 3 protocols include women with PCOS as a pre-specified subgroup in at least one trial arm, which represents a meaningful shift from earlier GLP-1 trial designs that excluded or under-enrolled women with PCOS.

2025: NDA Submission Expected, No Approval Yet

As of July 2025, Eli Lilly has stated plans to submit a New Drug Application (NDA) to the FDA, but that submission had not been publicly confirmed as filed at the time this article was reviewed. The FDA's Prescription Drug User Fee Act (PDUFA) review clock (typically 10 to 12 months for standard review, 6 months for priority review) would begin only after NDA acceptance.

The European Medicines Agency (EMA) has also received scientific advice requests from Lilly, but no Marketing Authorisation Application (MAA) has been formally submitted or acknowledged as of this review date.

What the Current Label Says (and Does Not Say)

There is no FDA-approved label for retatrutide. Any information circulating about dosing, indications, or contraindications is drawn from the Phase 2 protocol, the clinical trial registry at ClinicalTrials.gov, or Eli Lilly press materials, not from a finalized package insert reviewed and approved by regulators.

What Phase 2 Protocol Documents Reveal

The Phase 2 protocol used a dose-escalation schedule starting at 1 mg once weekly, escalating over several weeks through 2 mg, 4 mg, and 8 mg, up to a maximum dose of 12 mg once weekly. Subcutaneous injection was the delivery route. This escalation approach is consistent with FDA guidance on GLP-1 class drugs designed to limit early gastrointestinal tolerability problems.

What the NDA Will Likely Address

Based on publicly available trial registration data and the Jastreboff et al. Publication, the expected NDA will cover:

• Chronic weight management in adults with BMI <30 kg/m² and at least one weight-related comorbidity, or BMI <27 kg/m² alone (thresholds pending final FDA negotiation)
• Glycemic management in adults with type 2 diabetes (separate indication or combined labeling, depending on Phase 3 data)
• A risk evaluation and mitigation strategy (REMS) program for thyroid C-cell tumor risk, consistent with other GLP-1 receptor agonists in the class

Pregnancy, Lactation, and Contraception: What Women Must Know

Retatrutide is not approved for use during pregnancy. Women of reproductive potential should use effective contraception during treatment.

This is not a formality. It reflects real biological concern based on both mechanism and class data.

Mechanism-Based Concern

Glucagon receptor activation affects hepatic glucose production and fetal development pathways. GLP-1 receptor agonists as a class have shown fetal growth restriction and skeletal abnormalities in animal reproductive studies at clinically relevant exposures. FDA class labeling for GLP-1 receptor agonists such as semaglutide recommends discontinuing the drug at least two months before a planned pregnancy because of the drug's long half-life and the potential for fetal exposure during early organogenesis before a pregnancy is confirmed.

Retatrutide's half-life is approximately six days based on Phase 1 data. That is shorter than semaglutide (approximately seven days) but still long enough to require a washout period before attempting conception.

What to Tell Your Clinician If You Are Trying to Conceive

If you are in the reproductive years and using retatrutide in a clinical trial or off-label context:

• Discuss a formal contraception plan before starting any dose
• Plan a minimum two-month washout before attempting pregnancy (the semaglutide precedent; the retatrutide-specific washout recommendation will appear in the final label)
• Notify your prescriber immediately if you become pregnant during treatment

Lactation

No human lactation data exist for retatrutide. Based on its molecular weight (a peptide of approximately 4 kDa), gut degradation would limit oral bioavailability in a breastfed infant, but systemic exposure in the infant cannot be ruled out without direct pharmacokinetic studies. The standard clinical recommendation for the GLP-1 class during lactation is to avoid use until more data are available. The Academy of Breastfeeding Medicine applies a precautionary framework to novel agents with no lactation data.

Postpartum Women

Postpartum weight retention is a significant driver of long-term obesity risk in women. The median weight retained at 12 months postpartum is approximately 1 to 3 kg above pre-pregnancy weight, but retention of 5 kg or more occurs in roughly 20% of women. If retatrutide is approved, postpartum women who are not breastfeeding and who are at least six weeks postpartum may become a target population, but no Phase 3 trial currently enrolls this group specifically.

Who This May Be Right For (and Who Should Wait)

Women Most Likely to Benefit

Based on Phase 2 data and the mechanistic profile:

• Women with obesity (BMI <30 kg/m²) and type 2 diabetes who have not reached glycemic or weight targets on GLP-1 monotherapy
• Women with PCOS carrying significant visceral adiposity and insulin resistance. PCOS affects 8% to 13% of reproductive-age women and is the most common endocrine disorder in this group, yet it has been systematically excluded from or under-represented in most GLP-1 key trials
• Perimenopausal women with accelerating weight gain driven by declining estrogen and the associated shift toward central adiposity
• Women who stopped responding adequately to semaglutide or tirzepatide and require a higher-intensity metabolic signal

Women Who Should Wait or Are Excluded

• Pregnant women or those planning pregnancy in the near term
• Women currently breastfeeding
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, consistent with GLP-1 class contraindications
• Women with active pancreatitis or a history of severe pancreatitis
• Anyone outside a clinical trial setting, because retatrutide is not yet approved

Safety Profile: What the Phase 2 Data Show for Women

Gastrointestinal Events

Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects. In Jastreboff et al., nausea occurred in 42% to 45% of participants at the 12 mg dose versus 14% in the placebo group. Women have higher baseline rates of nausea and vomiting with GLP-1 drugs compared with men, based on post-hoc analyses of semaglutide and liraglutide trials. This sex difference is not yet quantified for retatrutide.

Gallbladder Events

Rapid weight loss increases cholelithiasis risk. A meta-analysis of GLP-1 receptor agonist trials found a relative risk of 1.27 for cholelithiasis and cholecystitis versus placebo. Women already carry a baseline gallstone risk approximately two to three times higher than men, driven by estrogen's effect on bile composition. This means gallbladder monitoring deserves particular attention in women on retatrutide.

Thyroid C-Cell Risk

All GLP-1 receptor agonists carry an FDA Boxed Warning for thyroid C-cell tumors based on rodent carcinogenicity studies. Human epidemiologic data from a large French pharmacovigilance study suggested a small but statistically significant increase in medullary thyroid carcinoma risk with liraglutide and semaglutide. Women with pre-existing thyroid nodules or a family history of thyroid cancer need to discuss this specifically with their clinician before any GLP-1 or triple-agonist treatment.

Bone Density

Rapid weight loss from any cause reduces bone mineral density, and postmenopausal women already face accelerated bone loss. Data from the STEP program for semaglutide showed statistically non-significant decreases in total hip BMD at 68 weeks. Retatrutide has not published bone data from Phase 2. Women at risk for osteoporosis, particularly those in early menopause or with prior low-trauma fractures, should discuss baseline DEXA scanning with their clinician.

Heart Rate

The glucagon receptor component of retatrutide raises heart rate more than GLP-1-only drugs do. In Jastreboff et al., mean heart rate increased by approximately 3 to 5 beats per minute across dose groups. Women with baseline tachycardia, paroxysmal atrial fibrillation, or thyroid-related heart rate disorders should be monitored closely if they use retatrutide.

The Evidence Gap: Where Women's Data Is Thin

Women have historically been underrepresented in cardiometabolic drug trials. Retatrutide is a partial exception: the Phase 2 trial enrolled 54% women, and PCOS is a named subgroup in Phase 3. But specific gaps remain:

• No published sex-stratified pharmacokinetic data. Body composition differences (higher percent body fat in women) may change the volume of distribution and effective exposure.
• No data in perimenopausal or postmenopausal women specifically.
• No published data on the interaction between retatrutide and estrogen-based hormonal contraception, which matters because GLP-1 drugs can affect gastric motility in ways that theoretically reduce oral contraceptive absorption.
• No lactation pharmacokinetic study has been conducted or registered.
• Women with PCOS are enrolled in Phase 3 but results will not be available until 2026 or later.

Where data are extrapolated from the broader trial population or from class effects, the WomanRx editorial team flags this explicitly rather than presenting it as confirmed female-specific evidence.

How Retatrutide Fits Alongside Other Women's Metabolic Options

Women managing obesity in the context of hormonal conditions often use more than one approach. Here is where retatrutide sits relative to currently approved therapies:

| Drug | Receptor targets | Phase 2/3 weight loss | Women-specific trial data | |---|---|---|---| | Semaglutide (Wegovy) | GLP-1 | ~15% at 68 weeks | STEP program includes women; no sex-specific PK | | Tirzepatide (Zepbound) | GLP-1, GIP | ~21% at 72 weeks | SURMOUNT includes women; PCOS subgroup study ongoing | | Retatrutide | GLP-1, GIP, GCGR | ~24% at 48 weeks | Phase 2 (54% women); Phase 3 PCOS subgroup enrolled | | Orlistat | Lipase inhibitor | ~3% at 12 months | Women's Health Initiative data available |

Retatrutide's weight-loss signal is the strongest of any agent in late-stage development, but it does not yet have the long-term cardiovascular outcomes data that semaglutide has from SELECT or the five-year safety record now accumulating for tirzepatide.

What to Expect if Retatrutide Is Approved

If Eli Lilly submits an NDA in late 2025 and receives Priority Review designation, a PDUFA action date would fall approximately six months later, meaning a possible approval in mid-2026. Standard review would push that to late 2026.

Upon approval, the label will specify:

• The approved indication (chronic weight management, type 2 diabetes, or both)
• A Boxed Warning for thyroid C-cell tumors
• Contraindications including pregnancy, medullary thyroid carcinoma history, and MEN2
• A dosing titration schedule from the Phase 3 data
• A pregnancy exposure registry, which is standard for this drug class

The FDA Sentinel System will monitor real-world safety from the date of approval, including rare events not captured in the 48-week Phase 2 window or even the Phase 3 trials.

Women who are currently enrolled in TRIUMPH trials are contributing the data that will determine whether the label includes PCOS-specific language, perimenopausal-specific language, or stratified dosing by sex. Enrollment in those trials, where eligible, is one concrete way to accelerate the evidence base.